Alexandros Fotopoulos - Jun 15, 2023 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Role: Chief Technical Officer
Signature: /s/ Edgar Cale, Attorney-in-Fact
Stock symbol: PASG
Transactions as of: Jun 15, 2023
Transactions value $: -$3,778
Form type: 4
Date filed: 6/20/2023, 04:10 PM
Previous filing: Apr 5, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PASG	Common Stock	Options Exercise	$0	+12.5K	+61.74%	$0.00	32.7K	Jun 15, 2023	Direct	F1
transaction	PASG	Common Stock	Sale	-$3.78K	-4.05K	-12.37%	$0.93	28.7K	Jun 16, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PASG	Restricted Stock Units	Options Exercise	$0	-12.5K	-33.33%	$0.00	25K	Jun 15, 2023	Common Stock	12.5K		Direct	F1, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2	The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F3	1/4 of the RSUs vested on June 15, 2022, and the remainder vested or vests as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4	These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.